Update on adjuvant therapy in completely resected NSCLC patients

Thoracic Cancer

Jeong Uk Lim¹  Chang Dong Yeo² 

[1] Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea Seoul South Korea;Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea Seoul Republic of Korea;

关键词: adjuvant;    biomarker;    immunotherapy;    non‐small cell lung cancer;    osimertinib;   

DOI  :  10.1111/1759-7714.14277

来源: DOAJ

【 摘 要 】

Abstract In patients with completely resected non‐small cell lung cancer (NSCLC), postoperative adjuvant chemotherapy has been associated with improvement in survival by minimizing the risk of recurrence. For years, systemic chemotherapy including platinum based regimen has been a mainstay treatment modality of adjuvant treatment after complete resection. ADAURA study showed that among completely resected IB to IIIA NSCLC, disease‐free survival was significantly better in patients under adjuvant osimertinib than a placebo group. After the advent of a variety of new treatment regimens, such as third generation TKI and immunotherapy, the landscape of postoperative adjuvant treatment has been changing. In this review, we discuss some key issues regarding choice of adjuvant treatment after complete resection in NSCLC, and provide further updates on recent advances in treatment modalities.

【 授权许可】

Unknown